Dr. Samuel B. Brusca, M.D.
Critical Care Medicine (Critical Care Medicine (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- New York University School of Medicine (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 220
Licensed in California since 2020, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: New York University School of Medicine
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Critical Care Medicine (Internal Medicine) Physician primary
CA license A168461 (first issued 2020; current) -
Cardiovascular Disease Physician
CA license A168461 (first issued 2020; current) -
Internal Medicine Physician
CA license A168461 (first issued 2020; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UCSF Medical Center San Francisco, CA
- UCSF Health St. Mary's Hospital San Francisco, CA
Medical groups
- University of California San Francisco (1,839 clinicians)
- Regents of the University of California (732 clinicians)
- University Anesthesia Medical Group (408 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 220
- Services billed
- 810
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 372 | 102 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 36 | 32 |
| Critical care, each additional 30 minutes | 24 | 15 |
| Insertion of artery tube for blood sampling or infusion through skin | 17 | 16 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 15 | 12 |
| Insertion of tube in pulmonary artery for monitoring | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Furosemide Other prescribers in San Francisco, CA | 28 |
| Spironolactone Other prescribers in San Francisco, CA | 27 |
| Tadalafil | 15 |
| Atorvastatin Calcium Other prescribers in San Francisco, CA | 12 |
| Uptravi (selexipag) | 12 |
| Jardiance (empagliflozin) Other prescribers in San Francisco, CA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 10 payments worth $3,039 in total to this clinician.
| Actelion Pharmaceuticals US, Inc. | $2,817 |
|---|---|
| Abiomed | $119 |
| Merck Sharp & Dohme LLC | $85.14 |
| Angiodynamics, Inc. | $17.39 |
| Consulting Fee | $2,695 |
|---|---|
| Food and Beverage | $296 |
| Travel and Lodging | $47.88 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. May 17, 2025 | Consulting Fee UPTRAVI · Cardiology | $2,695 |
| Actelion Pharmaceuticals US, Inc. May 17, 2025 | Travel and Lodging UPTRAVI · Cardiology · travel to SAN FRANCISCO, CA · in-kind | $24.94 |
| Actelion Pharmaceuticals US, Inc. May 17, 2025 | Travel and Lodging UPTRAVI · Cardiology · travel to SAN FRANCISCO, CA · in-kind | $22.94 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $49,501 in research payments for these studies, mostly to the institutions running them.
- A Team-based Patient Engagement Approach to Selexipag Initiation and Maintenance in Pulmonary Arterial Hypertension
Actelion Pharmaceuticals US, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.